Literature DB >> 22150106

Docking and QSAR comparative studies of polycyclic aromatic hydrocarbons and other procarcinogen interactions with cytochromes P450 1A1 and 1B1.

J Gonzalez1, N Marchand-Geneste, J L Giraudel, T Shimada.   

Abstract

To obtain chemical clues on the process of bioactivation by cytochromes P450 1A1 and 1B1, some QSAR studies were carried out based on cellular experiments of the metabolic activation of polycyclic aromatic hydrocarbons and heterocyclic aromatic compounds by those enzymes. Firstly, the 3D structures of cytochromes 1A1 and 1B1 were built using homology modelling with a cytochrome 1A2 template. Using these structures, 32 ligands including heterocyclic aromatic compounds, polycyclic aromatic hydrocarbons and corresponding diols, were docked with LigandFit and CDOCKER algorithms. Binding mode analysis highlighted the importance of hydrophobic interactions and the hydrogen bonding network between cytochrome amino acids and docked molecules. Finally, for each enzyme, multilinear regression and artificial neural network QSAR models were developed and compared. These statistical models highlighted the importance of electronic, structural and energetic descriptors in metabolic activation process, and could be used for virtual screening of ligand databases. In the case of P450 1A1, the best model was obtained with artificial neural network analysis and gave an r (2) of 0.66 and an external prediction [Formula: see text] of 0.73. Concerning P450 1B1, artificial neural network analysis gave a much more robust model, associated with an r (2) value of 0.73 and an external prediction [Formula: see text] of 0.59.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22150106     DOI: 10.1080/1062936X.2011.636380

Source DB:  PubMed          Journal:  SAR QSAR Environ Res        ISSN: 1026-776X            Impact factor:   3.000


  7 in total

1.  Rational engineering of the fungal P450 monooxygenase CYP5136A3 to improve its oxidizing activity toward polycyclic aromatic hydrocarbons.

Authors:  Khajamohiddin Syed; Aleksey Porollo; David Miller; Jagjit S Yadav
Journal:  Protein Eng Des Sel       Date:  2013-07-31       Impact factor: 1.650

Review 2.  Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.

Authors:  Naiem T Issa; Henri Wathieu; Abiola Ojo; Stephen W Byers; Sivanesan Dakshanamurthy
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

3.  Dibenzyl trisulfide binds to and competitively inhibits the cytochrome P450 1A1 active site without impacting the expression of the aryl hydrocarbon receptor.

Authors:  Shaniece Wauchope; Monika A Roy; William Irvine; Isaac Morrison; Eileen Brantley; Maxine Gossell-Williams; Alicia R Timme-Laragy; Rupika Delgoda
Journal:  Toxicol Appl Pharmacol       Date:  2021-03-24       Impact factor: 4.219

Review 4.  Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.

Authors:  Jayalakshmi Sridhar; Navneet Goyal; Jiawang Liu; Maryam Foroozesh
Journal:  Molecules       Date:  2017-07-08       Impact factor: 4.411

Review 5.  Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.

Authors:  Jayalakshmi Sridhar; Jiawang Liu; Maryam Foroozesh; Cheryl L Klein Stevens
Journal:  Molecules       Date:  2012-08-03       Impact factor: 4.411

6.  Associations between CYP1A1 rs1048943 A > G and rs4646903 T > C genetic variations and colorectal cancer risk: Proof from 26 case-control studies.

Authors:  Xueru Zhu; Zhao Wang; Jing He; Weiye Wang; Wenji Xue; Yiwei Wang; Leizhen Zheng; Mei-Ling Zhu
Journal:  Oncotarget       Date:  2016-08-09

Review 7.  Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.

Authors:  Zbigniew Dutkiewicz; Renata Mikstacka
Journal:  Bioinorg Chem Appl       Date:  2018-07-25       Impact factor: 7.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.